LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Corcept Therapeutics Inc

Chiusa

SettoreSettore sanitario

73.21 -1.43

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

72.52

Massimo

75.47

Metriche Chiave

By Trading Economics

Entrata

-9.8M

21M

Vendite

-25M

157M

P/E

Media del settore

64.591

50.291

EPS

0.169

Margine di Profitto

13.069

Dipendenti

500

EBITDA

-22M

3.4M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+87.45% upside

Dividendi

By Dow Jones

Utili prossimi

28 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

165M

7.9B

Apertura precedente

74.64

Chiusura precedente

73.21

Notizie sul Sentiment di mercato

By Acuity

49%

51%

157 / 380 Classifica in Healthcare

Corcept Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 giu 2025, 20:51 UTC

Utili

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 giu 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

27 giu 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

27 giu 2025, 20:48 UTC

Discorsi di Mercato

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 giu 2025, 20:46 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

27 giu 2025, 20:46 UTC

Discorsi di Mercato

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 giu 2025, 19:31 UTC

Discorsi di Mercato

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 giu 2025, 19:19 UTC

Discorsi di Mercato

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 giu 2025, 19:16 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 giu 2025, 18:57 UTC

Acquisizioni, Fusioni, Takeovers

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 giu 2025, 18:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 giu 2025, 18:42 UTC

Discorsi di Mercato

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 giu 2025, 18:39 UTC

Discorsi di Mercato
Utili

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 giu 2025, 18:29 UTC

Discorsi di Mercato

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 giu 2025, 18:18 UTC

Discorsi di Mercato

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 giu 2025, 18:16 UTC

Discorsi di Mercato

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 giu 2025, 17:16 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 giu 2025, 17:08 UTC

Utili

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 giu 2025, 16:52 UTC

Acquisizioni, Fusioni, Takeovers

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 giu 2025, 16:22 UTC

Utili

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

27 giu 2025, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

27 giu 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

27 giu 2025, 15:59 UTC

Discorsi di Mercato

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 giu 2025, 15:56 UTC

Discorsi di Mercato

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Confronto tra pari

Modifica del prezzo

Corcept Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

87.45% in crescita

Previsioni per 12 mesi

Media 139.33 USD  87.45%

Alto 145 USD

Basso 131 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Corcept Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

4

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

157 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.